The CardioHealth Alliance welcomes Amgen as a new member and invites others to join in the effort to advance prevention and care.
The CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal, and metabolic diseases. The Alliance, established in 2020 by leaders from the Duke Clinical Research Institute (DCRI) and the Stanford Center for Clinical Research, welcomes Amgen as a new member and invites clinicians, patients, data scientists, health care leaders, and policy makers to partner to improve disease care pathways and expedite the implementation of evidence into practice.
“The CardioHealth Alliance provides a collaborative, multidisciplinary approach to treating heart disease, which remains the leading cause of death in the U.S.,” said Adrian Hernandez, MD, MHS, cardiologist and executive director of the DCRI. “By turning evidence into practice in real time, we can deliver transformative care that prevents cardiovascular and related diseases and accounts for the overall well-being of an individual.”
A broad portfolio of research will take place within the CardioHealth Alliance, leveraging existing partnerships with large health systems and other research institutions to expedite evidence-based solutions for prevention and care for a range of conditions, including cardiovascular, renal, and cardio-metabolic diseases. Initial institutional members of the Alliance include Allina Health, Duke University School of Medicine, Intermountain Healthcare, Ochsner Medical Center, Stanford University School of Medicine, and UPMC.
The Alliance’s key goals are to:
- Use real-world data to inform real-world care
- Develop and test new pathways and practices
- Scale and optimize best practices
- Continuously address value of care through effective policy
“Amgen is proud to join this transformative research alliance focused on implementation of evidence-based therapies into real-world clinical practice in order to address the growing burden of cardiovascular, renal, and metabolic diseases in the U.S.,” said Ponda Motsepe-Ditshego, General Medicine Vice President at Amgen. “We believe it is through such collaborations that we can address some of the biggest public health concerns.”
For more information, visit cardiohealthalliance.org or contact CardioHealthAlliance@dm.duke.edu.
About the Duke Clinical Research Institute (DCRI)
The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world. Our mission is to develop, share, and implement knowledge that improves global health through innovative clinical research. The institute conducts multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI is a pioneer in cardiovascular clinical research, and conducts groundbreaking clinical research across multiple other therapeutic areas, including infectious disease, neuroscience, respiratory medicine, and nephrology. The DCRI serves as the coordinating center for PCORnet®, The National Patient-Centered Clinical Research Network.